Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February

Zura Bio Limited (NASDAQ:ZURA) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 4,737,248 shares, an increase of 16.2% from the February 12th total of 4,075,644 shares. Based on an average daily trading volume, of 496,325 shares, the short-interest ratio is currently 9.5 days. Approximately 9.4% of the company’s shares are short sold. Approximately 9.4% of the company’s shares are short sold. Based on an average daily trading volume, of 496,325 shares, the short-interest ratio is currently 9.5 days.

Insider Buying and Selling

In related news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was bought at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the purchase, the insider directly owned 6,552,725 shares in the company, valued at $40,954,531.25. The trade was a 43.93% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 22.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Atika Capital Management LLC purchased a new stake in shares of Zura Bio in the third quarter worth about $1,195,000. Suvretta Capital Management LLC raised its holdings in shares of Zura Bio by 12.6% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,472,891 shares of the company’s stock valued at $23,698,000 after buying an additional 611,952 shares during the period. Alberta Investment Management Corp purchased a new stake in shares of Zura Bio during the 2nd quarter valued at about $140,000. Savant Capital LLC lifted its position in Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after acquiring an additional 21,249 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in Zura Bio during the 1st quarter worth approximately $72,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZURA has been the subject of a number of recent analyst reports. Wedbush started coverage on shares of Zura Bio in a report on Monday, February 9th. They issued an “outperform” rating and a $15.00 target price for the company. Leerink Partners raised shares of Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.60.

Zura Bio Trading Up 1.8%

Shares of ZURA stock opened at $6.28 on Tuesday. The company has a market cap of $408.33 million, a PE ratio of -9.66 and a beta of 0.18. The company’s fifty day simple moving average is $6.10 and its 200-day simple moving average is $4.45. Zura Bio has a 52 week low of $0.97 and a 52 week high of $7.44.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.